Gerdau 3Q26: North America Drives Margin to 20.2%, But Brazil Remains Silent

What happened

Gerdau reported 3Q26 adjusted EBITDA of R$3.8 billion, up 10% quarter-over-quarter, with a consolidated margin of 20.2%, the highest since 2Q23. The North America segment again contributed over 76% of EBITDA, confirming that the company's profitability remains heavily reliant on U.S. operations. The press release provides no detail on Brazil segment margins, import penetration, or trade-defense outcomes, leaving the key swing factor for future earnings unaddressed. While the margin improvement is a positive signal, it does not yet demonstrate the two-engine earnings profile the bull case requires. The stock likely reacts to the headline beat, but the underlying thesis remains anchored on North American backlog durability and Brazilian policy catalysts.

Implication

Investors should treat this release as evidence that the North American profit engine is still firing, but not as proof of a synchronized Americas recovery. The 20.2% margin is above the base-case assumption of North America holding above 20% and Brazil staying near 9-10%, but the company's silence on Brazil suggests the domestic business has not yet inflected. If next quarter shows Brazil margin above 10% or a binding trade remedy, the bull case strengthens; conversely, if backlog slips or free cash flow stays minimal, the bear case becomes more probable. At current price, the risk-reward is balanced, and the 3-6 month reassessment window should focus on project start-ups and policy news.

Thesis delta

The thesis shifts modestly positive on near-term earnings quality: consolidated EBITDA margin improved to 20.2% from under 18% in 1Q26, led by durable North America strength. However, the one-engine concentration has increased to over 76% of EBITDA, and the absence of Brazil recovery data means the strategic optionality remains unproven. Consequently, the WAIT rating is maintained, with upgrade triggers unchanged: Brazil margin above 10% or enforceable trade remedies.